These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 17452147)

  • 1. The Cobalt chromium STent with Antiproliferative for Restenosis II (COSTAR II) trial study design: advancing the active-control evaluation of second-generation drug-eluting stents.
    Wang TY; Hasselblad V; Peterson JL; Wijns W; Parhizgar A; Kereiakes DJ; Krucoff MW
    Am Heart J; 2007 May; 153(5):743-8. PubMed ID: 17452147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
    Krucoff MW; Kereiakes DJ; Petersen JL; Mehran R; Hasselblad V; Lansky AJ; Fitzgerald PJ; Garg J; Turco MA; Simonton CA; Verheye S; Dubois CL; Gammon R; Batchelor WB; O'Shaughnessy CD; Hermiller JB; Schofer J; Buchbinder M; Wijns W;
    J Am Coll Cardiol; 2008 Apr; 51(16):1543-52. PubMed ID: 18420096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct stenting with TAXUS stents seems to be as safe and effective as with predilatation. A post hoc analysis of TAXUS II.
    Silber S; Hamburger J; Grube E; Pfisterer M; Belardi J; Webb J; Zmudka K; Nienaber C; Hauptman K; Rutsch W; Dawkins K; Drzewiecki J; Koglin J; Colombo A
    Herz; 2004 Mar; 29(2):171-80. PubMed ID: 15057438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug-eluting stents for diabetic patients. A critical appraisal of the currently available data from randomized trials].
    Silber S; Herdeg C
    Herz; 2008 Apr; 33(3):196-205. PubMed ID: 18568314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease.
    Nikolsky E; Lansky AJ; Sudhir K; Doostzadeh J; Cutlip DE; Piana R; Su X; White R; Simonton CA; Stone GW
    Am Heart J; 2009 Oct; 158(4):520-526.e2. PubMed ID: 19781409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions.
    Silber S; Colombo A; Banning AP; Hauptmann K; Drzewiecki J; Grube E; Dudek D; Baim DS
    Circulation; 2009 Oct; 120(15):1498-504. PubMed ID: 19786634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cypher versus taxus: are there differences?
    Silber S
    J Interv Cardiol; 2005 Dec; 18(6):441-6. PubMed ID: 16336424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of the tacrolimus drug-eluting Janus stent: a prospective two-centre registry in high-risk patients.
    Romagnoli E; Leone AM; Burzotta F; Trani C; Angeloni G; Materazzo G; Niccoli G; De Vita M; Perfetti M; Mazzari MA; Mongiardo R; Rebuzzi AG; Schiavoni G; Crea F
    J Cardiovasc Med (Hagerstown); 2008 Jun; 9(6):589-94. PubMed ID: 18475127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) trial.
    Verheye S; Agostoni P; Dawkins KD; Dens J; Rutsch W; Carrie D; Schofer J; Lotan C; Dubois CL; Cohen SA; Fitzgerald PJ; Lansky AJ
    JACC Cardiovasc Interv; 2009 Mar; 2(3):205-14. PubMed ID: 19463427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which parameter should be chosen as primary endpoint for randomized drug-eluting stent studies?
    Silber S
    J Interv Cardiol; 2004 Dec; 17(6):375-85. PubMed ID: 15546289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The paclitaxel-eluting stent in percutaneous coronary intervention: part I: background and clinical comparison to bare metal stents.
    Gruchalla KJ; Nawarskas JJ
    Cardiol Rev; 2006; 14(2):88-98. PubMed ID: 16493246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus.
    Boyden TF; Nallamothu BK; Moscucci M; Chan PS; Grossman PM; Tsai TT; Chetcuti SJ; Bates ER; Gurm HS
    Am J Cardiol; 2007 May; 99(10):1399-402. PubMed ID: 17493468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of drug-eluting stents in the coronary artery in ST-elevation myocardial infarction at a single high-volume medical center.
    Bose R; Gupta G; Grayburn PA; Laible EA; Kang MJ; Choi JW
    Am J Cardiol; 2007 Sep; 100(6):949-52. PubMed ID: 17826375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year outcomes with the Taxus Liberté stent in the real world: the Taxus Olympia registry (phase I).
    Ahmed WH; Zambahari R; Al-Rashdan I; Al Naeemi A; Saeed FA; Mascioli S
    J Interv Cardiol; 2008 Dec; 21(6):512-8. PubMed ID: 18973513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.
    Schömig A; Dibra A; Windecker S; Mehilli J; Suárez de Lezo J; Kaiser C; Park SJ; Goy JJ; Lee JH; Di Lorenzo E; Wu J; Jüni P; Pfisterer ME; Meier B; Kastrati A
    J Am Coll Cardiol; 2007 Oct; 50(14):1373-80. PubMed ID: 17903638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.
    Byrne RA; Mehilli J; Iijima R; Schulz S; Pache J; Seyfarth M; Schömig A; Kastrati A
    Eur Heart J; 2009 Apr; 30(8):923-31. PubMed ID: 19240066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymer-based, paclitaxel-eluting TAXUS Liberté stent in de novo lesions: the pivotal TAXUS ATLAS trial.
    Turco MA; Ormiston JA; Popma JJ; Mandinov L; O'Shaughnessy CD; Mann T; McGarry TF; Wu CJ; Chan C; Webster MW; Hall JJ; Mishkel GJ; Cannon LA; Baim DS; Koglin J
    J Am Coll Cardiol; 2007 Apr; 49(16):1676-83. PubMed ID: 17448368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evidence on polymer-based sirolimus and paclitaxel eluting stents.
    Iijima R; Mehilli J; Schömig A; Kastrati A
    Minerva Cardioangiol; 2006 Oct; 54(5):539-55. PubMed ID: 17019392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the drug-eluting stent trials.
    Coolong A; Kuntz RE
    Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.